Foresee Pharmaceuticals Co (ROCO:6576) Total Liabilities : NT$560.2 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Foresee Pharmaceuticals Co Total Liabilities?

Foresee Pharmaceuticals Co's Total Liabilities for the quarter that ended in Dec. 2024 was NT$560.2 Mil.

Foresee Pharmaceuticals Co's quarterly Total Liabilities increased from Jun. 2024 (NT$593.11 Mil) to Sep. 2024 (NT$758.90 Mil) but then declined from Sep. 2024 (NT$758.90 Mil) to Dec. 2024 (NT$560.15 Mil).

Foresee Pharmaceuticals Co's annual Total Liabilities increased from Dec. 2022 (NT$393.43 Mil) to Dec. 2023 (NT$616.93 Mil) but then declined from Dec. 2023 (NT$616.93 Mil) to Dec. 2024 (NT$560.15 Mil).

Foresee Pharmaceuticals Co Total Liabilities Historical Data

The historical data trend for Foresee Pharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foresee Pharmaceuticals Co Total Liabilities Chart

Foresee Pharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

270.40

321.26

393.43

616.93

560.15

Foresee Pharmaceuticals Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															616.93	535.64	593.11	758.90	560.15

Foresee Pharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Foresee Pharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	393.209	+	(92.917	+	74.026
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	560.2

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	2159.152	-	1599
	=	560.2

Foresee Pharmaceuticals Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	393.209	+	(92.917	+	74.026
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	560.2

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	2159.152	-	1599
	=	560.2

Foresee Pharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Foresee Pharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Foresee Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Foresee Pharmaceuticals Co Ltd (ROCO:6576) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115

Website

https://www.foreseepharma.com

Foresee Pharmaceuticals Co Ltd is engaged in the development and commercialization of new drugs using its proprietary drug delivery technology. Its main activity is to apply its Stabilized injectable formulation(SIF) platform technology to produce the products for anticancer and treatment of chronic disease. Its SIF product pipeline includes FP-001 for prostate cancer, FP-004 for Opioid drug addiction/Pain, FP-011 for Breast Cancer/Prostate Cancer, FP-016 for neurological diseases, and others. All of its revenue is generated from Taiwan.

Foresee Pharmaceuticals Co Headlines

No Headlines